Thanks in part to federal funding for newborn hearing screening, about 98% of newborns are screened for hearing loss before ...

In this webinar – ‘Enabling Digitally Enhanced Care for Rare Diseases in Europe: Integrating AI and Connected Care ...

Argenx SE (NASDAQ:ARGX) showcased long-term data of Vyvgart (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) demonstrating sustained disease control of ...

Multiple failings led to a patient with Crohn's disease having a hysterectomy without giving informed consent, an ombudsman has found. The woman, in her early 40s, said it has left her feeling ...

He says this is a crucial time for brain disease research, as drugs are being developed that show potential to treat the underlying causes of Alzheimer's rather than just slowing its symptoms.

Beam to enroll 75 mg dose cohort and dose first liver disease patient in 2H 2025. China’s new tariffs just reignited the same market patterns that led to triple- and quadruple-digit wins for ...

This study validates criteria to identify patients with inflammatory bowel disease (IBD) at risk of worsening disease who may benefit from early treatment with advanced therapies. Objectives ...

63 Exercise training is an established, inexpensive, generally safe intervention capable of increasing exercise capacity and reducing symptoms in most patients with cardiovascular disease (the Table).

The COVID-19 pandemic has raised considerable concerns that patients with inflammatory bowel disease (IBD), particularly those treated with immunosuppressive therapies, may have an increased risk of ...

Patient-identifiable information was kept secure—the name ... two cases of neuroaxonal dystrophy and single cases of Krabbe disease, GM1 gangliosidosis, Alexander disease, Rasmussen encephalitis, ...

These patients are now enrolled in an open-label follow-up with ... The authors noted that the finding of 50 percent slower disease progression was robust, being unchanged after controlling for ...

Semaglutide, a GLP-1 receptor agonist, improves glycaemic control and cardiovascular outcomes in patients with type 2 diabetes and those with cardiovascular disease, including peripheral artery ...